Meeting
2024 ASCO Annual Meeting
A phase I dose escalation trial of BCD-145 in patients with unresectable or metastatic melanoma.
Authors
Fedor Kryukov
JSC Biocad, Saint Petersburg, Russian Federation
Fedor Kryukov , Tatiana Semiglazova , Vladimir Moiseenko , Svetlana Odintsova , Irina Sorokina , Ekaterina Menshchikova , Arina Zinkina-Orikhan , Anna Kushakova , Sergey Fogt
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Advanced/Metastatic Disease
Clinical Trial Registration Number
NCT03472027
Citation
J Clin Oncol 42, 2024 (suppl 16; abstr 9526)
DOI
10.1200/JCO.2024.42.16_suppl.9526
Abstract #
9526
Poster Bd #
310
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Annual Meeting
![EMITT-1: Proof-of-mechanism immunopeptidome (ImPD) effects at target PK exposure, in a phase 1 study of GRWD5769 (a first-in-class inhibitor of Endoplasmic Reticulum Aminopeptidase 1 [ERAP1]) in patients with solid malignancies.](https://d201v5jt9ylckg.cloudfront.net/316/15821/233888/233888_A322_poster_pv.jpg)
EMITT-1: Proof-of-mechanism immunopeptidome (ImPD) effects at target PK exposure, in a phase 1 study of GRWD5769 (a first-in-class inhibitor of Endoplasmic Reticulum Aminopeptidase 1 [ERAP1]) in patients with solid malignancies.
First Author: Thomas Lillie
Poster
2016 ASCO Annual Meeting
First in human (FIH) study of an OX40 agonist monoclonal antibody (mAb) PF-04518600 (PF-8600) in adult patients (pts) with select advanced solid tumors: Preliminary safety and pharmacokinetic (PK)/pharmacodynamic results.
First Author: Omid Hamid
Poster
2015 ASCO Annual Meeting
Dose-escalation of the first-in human phase I/Ib study of ABTL0812, a novel antitumor drug inhibiting the Akt/mTOR pathway in patients with advanced solid tumors.
First Author: Laura Vidal Boixader
Poster
2015 ASCO Annual Meeting
A phase 1 first-in-human (FIH) dose-escalation (DE) study of the oral dual PI3K/mTOR inhibitor PQR309 in patients (pts) with advanced solid tumors: Final DE results.
First Author: Rebecca Sophie Kristeleit